Pharmacologic overview of Withania somnifera, the Indian Ginseng

Cellular and Molecular Life Sciences

Volumn 72, Issue 23, 2015, Pages 4445-4460

  Dar, Nawab John ^a,b   Hamid, Abid ^a,b   Ahmad, Muzamil ^a,b  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Alzheimer's disease; Anti arthritic; Anti bacterial; Anti cancer; Anti diabetic; Anti inflammatory; Anti stress; Cardio protective; Parkinson's disease; Stroke hypoxia; Withania somnifera

Indexed keywords

WITHANIA SOMNIFERA EXTRACT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOTONIC AGENT; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; WITHAFERIN A; WITHANOLIDE;

ANTIALZHEIMER ACTIVITY; ANTIARTHRITIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIHYPOXIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIISCHEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPARASITIC ACTIVITY; ANTIPARKINSON ACTIVITY; AREA UNDER THE CURVE; CHEMICAL COMPOSITION; CLINICAL PHARMACOLOGY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; HEART PROTECTION; HUMAN; INDIA; MAXIMUM PLASMA CONCENTRATION; NEUROPROTECTION; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; WITHANIA SOMNIFERA; ALZHEIMER DISEASE; ANIMAL; AYURVEDA; CHEMISTRY; INFLAMMATION; MEDICINAL PLANT; PARKINSON DISEASE; WITHANIA;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARDIOTONIC AGENTS; HUMANS; INDIA; INFLAMMATION; MEDICINE, AYURVEDIC; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PLANTS, MEDICINAL; WITHANIA; WITHANOLIDES;

EID: 84946481358     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-2012-1     Document Type: Review

References (182)

1. Dhuley JN (1998) Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 60:173-178
2. Ziauddin M, Phansalkar N, Patki P, Diwanay S, Patwardhan B (1996) Studies on the immunomodulatory effects of Ashwagandha. J Ethnopharmacol 50:69-76
3. Hepper FN (1991) Old World Withania (Solanaceae): a taxonomic review and key to the species. In: Hawkes JG, Lester RN, Nee M, Estrada N (eds) Solanaceae III: taxonomy, chemistry, evolution. Royal Botanic Gardens Kew and Linnean Society of London, London
4. Purdie RW, Symon DE, Haegi L (1982) Solanaceae. Flora Aust 29:184
5. Van Wyk B-E, Wink M (2004) Medicinal plants of the world. Briza Publications, Pretoria
6. Uddin Q, Samiulla L, Singh V, Jamil S (2012) Phytochemical and pharmacological profile of Withania somnifera dunal: a review. J Appl Pharm Sci 02(01):170-175
7. Singh N, Bhalla M, de Jager P, Gilca M (2011) An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med 8(S):208-213
8. Changhadi GS (1938) Ashwagandharishta - Rastantra Sar Evam Sidhyaprayog Sangrah. Krishna-Gopal Ayurveda Bhawan (Dharmarth Trust), Nagpur, pp 743-774
9. Sharma PV (1999) Ashwagandha. Dravyaguna Vijana, Chaukhambha Viashwabharti Varanasi, pp 763-765
10. Bhandari CR (1970) Ashwagandha (Withania somnifera) Vanaushadhi Chandroday (An Encyclopedia of Indian Herbs), vol 1. CS Series, Varanasi Vidyavilas Press, Varanasi, India, pp 96-97
11. Basu KA (1935) Withania somnifera, Indian medicinal plants, 2nd edn. IIIrd Lalit Mohan Basu, Allahabad, pp 1774-1776
12. Mishra B (2004) Ashwagandha - Bhavprakash Nigantu (Indian Materia Medica). Varanasi, Chaukhambha Bharti Academy, pp 393-394
13. Sharma S, Dahanukar S, Karandikar S (1985) Effects of long-term administration of the roots of ashwagandha and shatavari in rats. Indian Drugs 22:133
14. Machiah DK, Girish K, Gowda TV (2006) A glycoprotein from a folk medicinal plant, Withania somnifera, inhibits hyaluronidase activity of snake venoms. Comp Biochem Physiol C Toxicol Pharmacol 143:158-161
15. Machiah DK, Gowda TV (2006) Purification of a post-synaptic neurotoxic phospholipase A 2 from Naja naja venom and its inhibition by a glycoprotein from Withania somnifera. Biochimie 88:701-710
16. Agarwal R, Diwanay S, Patki P, Patwardhan B (1999) Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol 67:27-35
17. Ali M, Shuaib M, Ansari SH (1997) Withanolides from the stem bark of Withania somnifera. Phytochemistry 44:1163-1168
18. Ghani N (1920) Khazain-ul-Adviyah, vol I. Munshi Nawal Kishore, Lucknow, pp 230-231
19. Kabiruddin M (1955) Makhzan-ul-Mufradat. Nadeem University Printers, Lahore, pp 75-76
20. Nadkarni KM (1982) Indian Materia Medica, 3rd edn, vol I. Popular Prakashan Pvt Ltd, Bombay, pp 1292-1294
21. Tiwari R, Chakraborty S, Saminathan M, Dhama K, Singh SV (2014) Ashwagandha (Withania somnifera): role in safeguarding health, immunomodulatory effects, combating infections and therapeutic applications: a review. J Biol Sci 14(2):77-94
22. Ven Murthy M, Ranjekar PK, Ramassamy C, Deshpande M (2010) Scientific basis for the use of Indian Ayurvedic medicinal plants in the treatment of neurodegenerative disorders: 1. Ashwagandha. Cent Nerv Syst Agents Med Chem 10:238-246
23. Seenivasagam R, Sathiyamoorthy S, Hemavathi K (2011) Therapeutic impacts of Indian and Korean ginseng on human beings - a review. Int J Immunol Stud 1:297-317
24. Grandhi A, Mujumdar AM, Patwardhan B (1994) A comparative pharmacological investigation of Ashwagandha and Ginseng. J Ethnopharmacol 44:131-135
25. Kaur K, Rani G, Widodo N, Nagpal A, Taira K et al (2004) Evaluation of the anti-proliferative and anti-oxidative activities of leaf extract from in vivo and in vitro raised Ashwagandha. Food Chem Toxicol 42:2015-2020
26. Chopra A, Lavin P, Patwardhan B, Chitre D (2004) A 32-week randomized, placebo-controlled clinical evaluation of RA-11, an Ayurvedic drug, on osteoarthritis of the knees. JCR J Clin Rheumatol 10:236-245
27. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J (2009) Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 14:2373-2393
28. Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5:334-346
29. Matsuda H, Murakami T, Kishi A, Yoshikawa M (2001) Structures of withanolides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorg Med Chem 9:1499-1507
30. Singh G, Sharma P, Dudhe R, Singh S (2010) Biological activities of Withania somnifera. Ann Biol Res 1:56-63
31. Bhattacharya SK, Goel RK, Kaur R, Ghosal S (1987) Anti-stress activity of sitoindosides VII and VIII, new acylsterylglucosides from Withania somnifera. Phytother Res 1:32-37
32. Ghosal S, Kaur R, Srivastava R (1988) Sito-indosides IX and X, two new glycowithanolides from Withania somnifera. Indian J Nat Prod 4:12-13
33. Majumdar D (1955) Withania somnifera Dunal, Part II. Alkaloidal constituents and their chemical characterization. Indian J Pharm 17:158-161
34. Praveen N, Murthy H (2010) Production of withanolide-A from adventitious root cultures of Withania somnifera. Acta Physiol Plant 32:1017-1022
35. Misra L, Mishra P, Pandey A, Sangwan RS, Sangwan NS et al (2008) Withanolides from Withania somnifera roots. Phytochemistry 69:1000-1004
36. Subbaraju GV, Vanisree M, Rao CV, Sivaramakrishna C, Sridhar P et al (2006) Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of Withania somnifera⊥. J Nat Prod 69:1790-1792
37. Anjaneyulu A, Rao D, Lequesne P (1998) Withanolides, biologically active natural steroidal lactones. Struct Chem Part F 20:135
38. Kirson I, Glotter E, Abraham A, Lavie D (1970) Constituents of Withania somnifera dun - XI: the structure of three new withanolides. Tetrahedron 26:2209-2219
39. Lavie D, Glotter E, Shvo Y (1965) Constituents of Withania somnifera Dun. III. The side chain of withaferin A, 1. J Org Chem 30:1774-1778
40. Lavie D, Kashman Y, Glotter E (1966) Constituents of Withania somnifera dun - V: studies on some model steroidal epoxides. Tetrahedron 22:1103-1111
41. Glotter E, Abraham A, Günzberg G, Kirson I (1977) Naturally occurring steroidal lactones with a 17α-oriented side chain. Structure of withanolide E and related compounds. J Chem Soc Perkin 1:341-346
42. Kirson I, Glotter E, Lavie D, Abraham A (1971) Constituents of Withania somnifera Dun: part XII. The withanolides of an Indian chemotype. J Chem Soc 2032-2044
43. Dhalla NS, Sastry MS, Malhotra CL (1961) Chemical studies of the leaves of Withania somnifera. J Pharm Sci 50:876-877
44. Pramanick S, Roy A, Ghosh S, Majumder HK, Mukhopadhyay S (2008) Withanolide Z, a new chlorinated withanolide from Withania somnifera. Planta Med 74:1745-1748
45. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG (2003) Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci 74:125-132
46. Jayaprakasam B, Nair MG (2003) Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron 59:841-849
47. Menssen H, Stapel G (1973) Uber ein C28-Steroidlacton aus der Wurzel von Withania Somnifera. Plant Med
48. Abou-Douh AM (2002) New withanolides and other constituents from the fruit of Withania somnifera. Arch Pharm 335(6):267-276
49. Kundu AB, Mukherjee A, Dey A (1976) New Withanolide from seeds of Withania-somnifera dunal. Indian J Chem 14:434-435
50. Jayaprakasam B, Strasburg GA, Nair MG (2004) Potent lipid peroxidation inhibitors from Withania somnifera fruits. Tetrahedron 60:3109-3121
51. Xu Y-M, Marron MT, Seddon E, McLaughlin SP, Ray DT et al (2009) 2, 3-Dihydrowithaferin A-3β-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg Med Chem 17:2210-2214
52. Khan F, Saeed M, Alam M, Chaudhry A (1993) Biological studies of indigenous medicinal plants III. Phytochemical and antimicrobial studies on the non-alkaloidal constituents of some solanaceous fruits. Eczacilik Fakultesi Dergisi-Gazi Universitesi 10:105
53. Prabu PC, Panchapakesan S, Raj CD (2013) Acute and sub-acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytother Res 27:1169-1178
54. Prabu PC, Panchapakesan S (2015) Prenatal developmental toxicity evaluation of Withania somnifera root extract in Wistar rats. Drug Chem Toxicol 38:50-56
55. Sharada A, Solomon FE, Devi PU (1993) Toxicity of Withania somnifera root extract in rats and mice. Pharm Biol 31:205-212
56. Patil D, Gautam M, Mishra S, Karupothula S, Gairola S et al (2013) Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract. J Pharm Biomed Anal 80:203-212
57. Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P et al (2011) Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer 129:2744-2755
58. Dahikar PR, Kumar N, Sahni Y (2012) Pharmacokinetics of Withania somnifera (ashwagandha) in healthy buffalo calves. Buffalo Bull 31:219
59. Sumanth M, Nedunuri S (2014) Comparison of bioavailability and bioequivalence of herbal anxiolytic drugs with marketed drug alprazolam. World J Pharm Res 3:1358-1366
60. Bisht P, Rawat V (2014) Antibacterial activity of Withania somnifera against Gram-positive isolates from pus samples. Ayu 35:330
61. Singh G, Kumar P (2011) Evaluation of antimicrobial efficacy of flavonoids of Withania somnifera L. Indian J Pharm Sci 73:473
62. Alam N, Hossain M, Mottalib MA, Sulaiman SA, Gan SH et al (2012) Methanolic extracts of Withania somnifera leaves, fruits and roots possess antioxidant properties and antibacterial activities. BMC Complement Altern Med 12:175
63. Mwitari PG, Ayeka PA, Ondicho J, Matu EN, Bii CC (2013) Antimicrobial activity and probable mechanisms of action of medicinal plants of Kenya: Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus. PLoS One 8(6):e65619
64. Owais M, Sharad K, Shehbaz A, Saleemuddin M (2005) Antibacterial efficacy of Withania somnifera (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine 12:229-235
65. Arora S, Dhillon S, Rani G, Nagpal A (2004) The in vitro antibacterial/synergistic activities of Withania somnifera extracts. Fitoterapia 75:385-388
66. Pandit S, Chang K-W, Jeon J-G (2013) Effects of Withania somnifera on the growth and virulence properties of Streptococcus mutans and Streptococcus sobrinus at sub-MIC levels. Anaerobe 19:1-8
67. Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R (2013) An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int 62:253-261
68. Grover A, Katiyar SP, Jeyakanthan J, Dubey VK, Sundar D (2012) Blocking Protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera. BMC Genom 13:S20
69. El-On J, Ozer L, Gopas J, Sneir R, Enav H et al (2009) Antileishmanial activity in Israeli plants. Ann Trop Med Parasitol 103:297-306
70. Sachdeva H, Sehgal R, Kaur S (2013) Studies on the protective and immunomodulatory efficacy of Withania somnifera along with cisplatin against experimental visceral leishmaniasis. Parasitol Res 112:2269-2280
71. Dikasso D, Makonnen E, Debella A, Abebe D, Urga K et al (2006) Anti-malarial activity of Withania somnifera L. Dunal extracts in mice. Ethiop Med J 44:279-285
72. Muregi FW, Ishih A, Suzuki T, Kino H, Amano T et al (2007) In Vivo antimalarial activity of aqueous extracts from Kenyan medicinal plants and their Chloroquine (CQ) potentiation effects against a blood-induced CQ-resistant rodent parasite in mice. Phytother Res 21:337-343
73. Girish K, Machiah K, Ushanandini S, Harish Kumar K, Nagaraju S et al (2006) Antimicrobial properties of a non-toxic glycoprotein (WSG) from Withania somnifera (Ashwagandha). J Basic Microbiol 46:365-374
74. Pawar P, Gilda S, Sharma S, Jagtap S, Paradkar A et al (2011) Rectal gel application of Withania somnifera root extract expounds anti-inflammatory and muco-restorative activity in TNBS-induced inflammatory bowel disease. BMC Complement Altern Med 11:34
75. Minhas U, Minz R, Bhatnagar A (2011) Prophylactic effect of Withania somnifera on inflammation in a non-autoimmune prone murine model of lupus. Drug Discov Ther 5:195-201
76. Minhas U, Minz R, Das P, Bhatnagar A (2012) Therapeutic effect of Withania somnifera on pristane-induced model of SLE. Inflammopharmacology 20:195-205
77. Ku SK, Han MS, Bae JS (2014) Withaferin A is an inhibitor of endothelial protein C receptor shedding in vitro and in vivo. Food Chem Toxicol 68:23-29
78. Lee W, Kim TH, Ku SK, Min KJ, Lee HS et al (2012) Barrier protective effects of withaferin A in HMGB1-induced inflammatory responses in both cellular and animal models. Toxicol Appl Pharmacol 262:91-98
79. Kaileh M, Vanden Berghe W, Heyerick A, Horion J, Piette J et al (2007) Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 282:4253-4264
80. Oh JH, Kwon TK (2009) Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol 9:614-619
81. Heyninck K, Lahtela-Kakkonen M, Van der Veken P, Haegeman G, Vanden Berghe W (2014) Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKbeta. Biochem Pharmacol 91:501-509
82. Maitra R, Porter MA, Huang S, Gilmour BP (2009) Inhibition of NFkappaB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. J Inflamm (Lond) 6:15
83. Sumantran VN, Kulkarni A, Boddul S, Chinchwade T, Koppikar SJ et al (2007) Chondroprotective potential of root extracts of Withania somnifera in osteoarthritis. J Biosci 32:299-307
84. Sumantran VN, Chandwaskar R, Joshi AK, Boddul S, Patwardhan B et al (2008) The relationship between chondroprotective and antiinflammatory effects of Withania somnifera root and glucosamine sulphate on human osteoarthritic cartilage in vitro. Phytother Res 22:1342-1348
85. Singh D, Aggarwal A, Maurya R, Naik S (2007) Withania somnifera inhibits NF-kappaB and AP-1 transcription factors in human peripheral blood and synovial fluid mononuclear cells. Phytother Res 21:905-913
86. Rasool M, Varalakshmi P (2007) Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol 21:157-164
87. Khan MA, Subramaneyaan M, Arora VK, Banerjee BD, Ahmed RS (2015) Effect of Withania somnifera (Ashwagandha) root extract on amelioration of oxidative stress and autoantibodies production in collagen-induced arthritic rats. J Complement Integr Med 12:117-125
88. Gupta A, Singh S (2014) Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol 52:308-320
89. Dey D, Chaskar S, Athavale N, Chitre D (2014) Inhibition of LPS-induced TNF-alpha and NO production in mouse macrophage and inflammatory response in rat animal models by a novel Ayurvedic formulation, BV-9238. Phytother Res 28:1479-1485
90. Ganesan K, Sehgal PK, Mandal AB, Sayeed S (2011) Protective effect of Withania somnifera and Cardiospermum halicacabum extracts against collagenolytic degradation of collagen. Appl Biochem Biotechnol 165:1075-1091
91. Kim JH, Kim SJ (2014) Overexpression of microRNA-25 by withaferin A induces cyclooxygenase-2 expression in rabbit articular chondrocytes. J Pharmacol Sci 125:83-90
92. Yu SM, Kim SJ (2013) Production of reactive oxygen species by withaferin A causes loss of type collagen expression and COX-2 expression through the PI3 K/Akt, p38, and JNK pathways in rabbit articular chondrocytes. Exp Cell Res 319:2822-2834
93. Yu SM, Kim SJ (2014) Withaferin A-caused production of intracellular reactive oxygen species modulates apoptosis via PI3K/Akt and JNKinase in rabbit articular chondrocytes. J Korean Med Sci 29:1042-1053
94. Vaishnavi K, Saxena N, Shah N, Singh R, Manjunath K et al (2012) Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences. PLoS One 7:e44419
95. Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC et al (2008) Selective killing of cancer cells by leaf extract of Ashwagandha: components, activity and pathway analyses. Cancer Lett 262:37-47
96. Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S et al (2011) Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 16:1014-1027
97. Malik F, Kumar A, Bhushan S, Khan S, Bhatia A et al (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12:2115-2133
98. Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK (2011) Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. Toxicol In Vitro 25:1803-1810
99. Hahm ER, Lee J, Singh SV (2014) Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. Mol Carcinog 53:907-916
100. Yang ES, Choi MJ, Kim JH, Choi KS, Kwon TK (2011) Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. Chem Biol Interact 190:9-15
101. Choi MJ, Park EJ, Min KJ, Park JW, Kwon TK (2011) Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells. Toxicol In Vitro 25:692-698
102. Kim SH, Singh SV (2014) Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res (Phila) 7:738-747
103. Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA et al (2013) Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model. J Natl Cancer Inst 105:1111-1122
104. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S et al (2011) Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One 6:e23354
105. Hahm ER, Singh SV (2013) Autophagy fails to alter withaferin A-mediated lethality in human breast cancer cells. Curr Cancer Drug Targets 13:640-650
106. Lee J, Sehrawat A, Singh SV (2012) Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat 136:45-56
107. Stan SD, Zeng Y, Singh SV (2008) Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr Cancer 60(Suppl 1):51-60
108. Nagalingam A, Kuppusamy P, Singh SV, Sharma D, Saxena NK (2014) Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Cancer Res 74:2617-2629
109. Lee JH, Kim JE, Jang YJ, Lee CC, Lim TG et al (2015) Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K. Mol Carcinog. doi: 10.1002/mc.22302
110. Antony ML, Lee J, Hahm ER, Kim SH, Marcus AI et al (2014) Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with down-regulation and covalent binding at cysteine 303 of beta-tubulin. J Biol Chem 289:1852-1865
111. Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V et al (2006) Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol 105:336-341
112. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ et al (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7:115-122
113. Yang H, Wang Y, Cheryan VT, Wu W, Cui CQ et al (2012) Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo. PLoS One 7:e41214
114. Um HJ, Min KJ, Kim DE, Kwon TK (2012) Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem Biophys Res Commun 427:24-29
115. Das PK, Malhotra CL, Prasad K (1964) Cardiotonic activity of Ashwagandhine and Ashwagandhinine, two alkaloids from Withania ashwagandha, Kaul. Arch Int Pharmacodyn Ther 150:356-362
116. Ojha SK, Arya DS (2009) Withania somnifera Dunal (Ashwagandha): a promising remedy for cardiovascular diseases. World J Med Sci 4:156-158
117. Prince PSM, Suman S, Devika PT, Vaithianathan M (2008) Cardioprotective effect of 'Marutham'a polyherbal formulation on isoproterenol induced myocardial infarction in Wistar rats. Fitoterapia 79:433-438
118. Thirunavukkarasu M, Penumathsa S, Juhasz B, Zhan L, Bagchi M et al (2006) Enhanced cardiovascular function and energy level by a novel chromium (III)-supplement. BioFactors 27:53-67
119. Mohan IK, Kumar KV, Naidu MU, Khan M, Sundaram C (2006) Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice. Phytomedicine 13:222-229
120. Reuland DJ, Khademi S, Castle CJ, Irwin DC, McCord JM et al (2013) Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Radic Biol Med 56:102-111
121. Aphale AA, Chhibba AD, Kumbhakarna NR, Mateenuddin M, Dahat SH (1998) Subacute toxicity study of the combination of ginseng (Panax ginseng) and ashwagandha (Withania somnifera) in rats: a safety assessment. Indian J Physiol Pharmacol 42:299-302
122. Mohanty IR, Arya DS, Gupta SK (2008) Withania somnifera provides cardioprotection and attenuates ischemia-reperfusion induced apoptosis. Clin Nutr 27:635-642
123. Gupta SK, Mohanty I, Talwar KK, Dinda A, Joshi S et al (2004) Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol Cell Biochem 260:39-47
124. Mohanty I, Arya DS, Dinda A, Talwar KK, Joshi S et al (2004) Mechanisms of cardioprotective effect of Withania somnifera in experimentally induced myocardial infarction. Basic Clin Pharmacol Toxicol 94:184-190
125. Ashour OM, Abdel-Naim AB, Abdallah HM, Nagy AA, Mohamadin AM et al (2012) Evaluation of the potential cardioprotective activity of some Saudi plants against doxorubicin toxicity. Z Naturforsch C 67:297-307
126. Hamza A, Amin A, Daoud S (2008) The protective effect of a purified extract of Withania somnifera against doxorubicin-induced cardiac toxicity in rats. Cell Biol Toxicol 24:63-73
127. Gauttam VK, Kalia AN (2013) Development of polyherbal antidiabetic formulation encapsulated in the phospholipids vesicle system. J Adv Pharm Technol Res 4:108-117
128. Mutalik S, Chetana M, Sulochana B, Devi PU, Udupa N (2005) Effect of Dianex, a herbal formulation on experimentally induced diabetes mellitus. Phytother Res 19:409-415
129. Bhattacharya SK, Satyan KS, Chakrabarti A (1997) Effect of Trasina, an Ayurvedic herbal formulation, on pancreatic islet superoxide dismutase activity in hyperglycaemic rats. Indian J Exp Biol 35:297-299
130. Andallu B, Radhika B (2000) Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root. Indian J Exp Biol 38:607-609
131. Anwer T, Sharma M, Pillai KK, Iqbal M (2008) Effect of Withania somnifera on insulin sensitivity in non-insulin-dependent diabetes mellitus rats. Basic Clin Pharmacol Toxicol 102:498-503
132. Gorelick J, Rosenberg R, Smotrich A, Hanus L, Bernstein N (2015) Hypoglycemic activity of withanolides and elicitated Withania somnifera. Phytochemistry
133. Udayakumar R, Kasthurirengan S, Mariashibu TS, Rajesh M, Anbazhagan VR, Kim SC, Ganapathi A, Choi CW (2009) Hypoglycaemic and hypolipidaemic effects of Withania somnifera root and leaf extracts on alloxan-induced diabetic rats. Int J Mol Sci 10(5):2367-2382. doi: 10.3390/ijms10052367
134. Udayakumar R, Kasthurirengan S, Vasudevan A, Mariashibu TS, Rayan JJ et al (2010) Antioxidant effect of dietary supplement Withania somnifera L. reduce blood glucose levels in alloxan-induced diabetic rats. Plant Foods Hum Nutr 65:91-98
135. SoRelle JA, Itoh T, Peng H, Kanak MA, Sugimoto K et al (2013) Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia 56:814-824
136. Babu PV, Gokulakrishnan A, Dhandayuthabani R, Ameethkhan D, Kumar CV et al (2007) Protective effect of Withania somnifera (Solanaceae) on collagen glycation and cross-linking. Comp Biochem Physiol B Biochem Mol Biol 147:308-313
137. Bhattacharya SK, Kumar A, Ghosal S (1995) Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 9:110-113
138. Kaur P, Mathur S, Sharma M, Tiwari M, Srivastava KK et al (2001) A biologically active constituent of Withania somnifera (ashwagandha) with antistress activity. Indian J Clin Biochem 16:195-198
139. Singh B, Saxena AK, Chandan BK, Gupta DK, Bhutani KK et al (2001) Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of Withania somnifera Dun. Phytother Res 15:311-318
140. Khan B, Ahmad SF, Bani S, Kaul A, Suri KA et al (2006) Augmentation and proliferation of T lymphocytes and Th-1 cytokines by Withania somnifera in stressed mice. Int Immunopharmacol 6:1394-1403
141. Chandrasekhar K, Kapoor J, Anishetty S (2012) A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med 34:255-262
142. Bhattacharya A, Muruganandam AV, Kumar V, Bhattacharya SK (2002) Effect of poly herbal formulation, EuMil, on neurochemical perturbations induced by chronic stress. Indian J Exp Biol 40:1161-1163
143. Muruganandam AV, Kumar V, Bhattacharya SK (2002) Effect of poly herbal formulation, EuMil, on chronic stress-induced homeostatic perturbations in rats. Indian J Exp Biol 40:1151-1160
144. Ramanathan M, Balaji B, Justin A (2011) Behavioural and neurochemical evaluation of Perment an herbal formulation in chronic unpredictable mild stress induced depressive model. Indian J Exp Biol 49:269-275
145. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S (2000) Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine 7:463-469
146. Bhattacharya A, Ghosal S, Bhattacharya SK (2001) Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 74:1-6
147. Durg S, Dhadde SB, Vandal R, Shivakumar BS, Charan CS (2015) Withania somnifera (Ashwagandha) in neurobehavioural disorders induced by brain oxidative stress in rodents: a systematic review and meta-analysis. J Pharm Pharmacol
148. Wollen KA (2010) Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev 15(3):223-244
149. Singh RH, Narsimhamurthy K, Singh G (2008) Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology 9:369-374
150. Kuboyama T, Tohda C, Komatsu K (2014) Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. Biol Pharm Bull 37:892-897
151. Konar A, Shah N, Singh R, Saxena N, Kaul SC et al (2011) Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One 6:e27265
152. Kumar P, Singh R, Nazmi A, Lakhanpal D, Kataria H et al (2014) Glioprotective effects of Ashwagandha leaf extract against lead induced toxicity. Biomed Res Int 2014:182029
153. Bhattacharya SK, Satyan KS (1997) Experimental methods for evaluation of psychotropic agents in rodents: I-Anti-anxiety agents. Indian J Exp Biol 35:565-575
154. Parihar MS, Hemnani T (2004) Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11:456-467
155. Jain S, Shukla SD, Sharma K, Bhatnagar M (2001) Neuroprotective effects of Withania somnifera Dunn in hippocampal sub-regions of female albino rat. Phytother Res 15:544-548
156. Zhao J, Nakamura N, Hattori M, Kuboyama T, Tohda C et al (2002) Withanolide derivatives from the roots of Withania somnifera and their neurite outgrowth activities. Chem Pharm Bull (Tokyo) 50:760-765
157. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M et al (2002) Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. NeuroReport 13:1715-1720
158. Kuboyama T, Tohda C, Komatsu K (2006) Withanoside IV and its active metabolite, sominone, attenuate Abeta(25-35)-induced neurodegeneration. Eur J Neurosci 23:1417-1426
159. Kataria H, Wadhwa R, Kaul SC, Kaur G (2012) Water extract from the leaves of Withania somnifera protect RA differentiated C6 and IMR-32 cells against glutamate-induced excitotoxicity. PLoS One 7:e37080
160. Parihar MS, Hemnani T (2003) Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. J Biosci 28:121-128
161. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S et al (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol 24:137-147
162. Sankar SR, Manivasagam T, Krishnamurti A, Ramanathan M (2007) The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell Mol Biol Lett 12:473-481
163. RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R et al (2009) Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. J Ethnopharmacol 125:369-373
164. Rajasankar S, Manivasagam T, Surendran S (2009) Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neurosci Lett 454:11-15
165. Manjunath MJ, Muralidhara (2015) Standardized extract of Withania somnifera (Ashwagandha) markedly offsets rotenone-induced locomotor deficits, oxidative impairments and neurotoxicity in Drosophila melanogaster. J Food Sci Technol 52:1971-1981
166. Manjunath MJ, Muralidhara (2013) Effect of Withania somnifera supplementation on rotenone-induced oxidative damage in cerebellum and striatum of the male mice brain. Cent Nerv Syst Agents Med Chem 13:43-56
167. Prakash J, Chouhan S, Yadav SK, Westfall S, Rai SN et al (2014) Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons. Neurochem Res 39:2527-2536
168. Prakash J, Yadav SK, Chouhan S, Singh SP (2013) Neuroprotective role of Withania somnifera root extract in maneb-paraquat induced mouse model of parkinsonism. Neurochem Res 38:972-980
169. Pingali U, Pilli R, Fatima N (2014) Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Res 6:12-18
170. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT et al (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 109:3510-3515
171. Jayaprakasam B, Padmanabhan K, Nair MG (2010) Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease. Phytother Res 24:859-863
172. Grover A, Shandilya A, Agrawal V, Bisaria VS, Sundar D (2012) Computational evidence to inhibition of human acetyl cholinesterase by withanolide a for Alzheimer treatment. J Biomol Struct Dyn 29:651-662
173. Yadav CS, Kumar V, Suke SG, Ahmed RS, Mediratta PK et al (2010) Propoxur-induced acetylcholine esterase inhibition and impairment of cognitive function: attenuation by Withania somnifera. Indian J Biochem Biophys 47:117-120
174. Ahmed ME, Javed H, Khan MM, Vaibhav K, Ahmad A et al (2013) Attenuation of oxidative damage-associated cognitive decline by Withania somnifera in rat model of streptozotocin-induced cognitive impairment. Protoplasma 250:1067-1078
175. Kurapati KR, Atluri VS, Samikkannu T, Nair MP (2013) Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-associated neurocognitive disorders (HAND). PLoS One 8:e77624
176. Kurapati KR, Samikkannu T, Atluri VS, Kaftanovskaya E, Yndart A et al (2014) beta-Amyloid1-42, HIV-1Ba-L (clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (Withania somnifera) and its constituent Withanolide A. PLoS One 9:e112818
177. Kumar S, Seal CJ, Howes MJ, Kite GC, Okello EJ (2010) In vitro protective effects of Withania somnifera (L.) dunal root extract against hydrogen peroxide and beta-amyloid(1-42)-induced cytotoxicity in differentiated PC12 cells. Phytother Res 24:1567-1574
178. Chaudhary G, Sharma U, Jagannathan NR, Gupta YK (2003) Evaluation of Withania somnifera in a middle cerebral artery occlusion model of stroke in rats. Clin Exp Pharmacol Physiol 30:399-404
179. Raghavan A, Shah ZA (2014) Withania somnifera improves ischemic stroke outcomes by attenuating PARP1-AIF-mediated caspase-independent Apoptosis. Mol Neurobiol. doi: 10.1007/s12035-014-8907-2
180. Raghavan A, Shah ZA (2015) Withania somnifera: a pre-clinical study on neuroregenerative therapy for stroke. Neural Regen Res 10:183-185
181. Baitharu I, Jain V, Deep SN, Hota KB, Hota SK et al (2013) Withania somnifera root extract ameliorates hypobaric hypoxia induced memory impairment in rats. J Ethnopharmacol 145:431-441
182. Baitharu I, Jain V, Deep SN, Shroff S, Sahu JK et al (2014) Withanolide A prevents neurodegeneration by modulating hippocampal glutathione biosynthesis during hypoxia. PLoS One 9:e105311